MCID: NRV006
MIFTS: 60

Nervous System Cancer malady

Categories: Cancer diseases, Neuronal diseases

Aliases & Classifications for Nervous System Cancer

Aliases & Descriptions for Nervous System Cancer:

Name: Nervous System Cancer 12 14
Nervous System Neoplasm 12 29
Neuroepithelial, Perineurial, and Schwann Cell Neoplasm 69
Malignant Neoplasm of Nervous System 12
Tumor of the Nervous System 12
Neoplasm of Nervous System 12
Nervous System Neoplasms 69
Neoplasms, Nerve Tissue 42
Nervous System--Cancer 69
Nervous System Tumor 52
Neural Neoplasm 12
Neural Tumor 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3093
ICD9CM 35 192 192.9
MeSH 42 D009380
NCIt 47 C35562
SNOMED-CT 64 188306000

Summaries for Nervous System Cancer

Disease Ontology : 12 An organ system cancer located in the nervous system that affects the central or peripheral nervous system.

MalaCards based summary : Nervous System Cancer, also known as nervous system neoplasm, is related to autonomic nervous system neoplasm and olfactory neural tumor. An important gene associated with Nervous System Cancer is NF1 (Neurofibromin 1), and among its related pathways/superpathways are ERK Signaling and GPCR Pathway. The drugs Cisplatin and Dacarbazine have been mentioned in the context of this disorder. Affiliated tissues include brain and the nervous system, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and cellular

Related Diseases for Nervous System Cancer

Diseases in the Nervous System Cancer family:

Nervous System Benign Neoplasm

Diseases related to Nervous System Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 148)
id Related Disease Score Top Affiliating Genes
1 autonomic nervous system neoplasm 33.7 CCND1 CDKN1A CDKN2A CDKN2B RB1 TP53
2 olfactory neural tumor 11.9
3 mismatch repair cancer syndrome 10.9
4 rapid-onset childhood obesity-hypothalamic dysfunction-hypoventilation-autonomic dysregulation syndrome 10.8
5 central neurocytoma 10.7
6 ectomesenchymoma 10.7
7 malignant ectomesenchymoma 10.7
8 schwannomatosis 10.7
9 ewing sarcoma 10.7
10 sensory system cancer 10.7
11 peripheral nervous system neoplasm 10.7
12 brain cancer 10.7
13 spinal cancer 10.7
14 meningioma, familial 10.7
15 male infertility 10.4 BCL2 CCND1
16 neurodevelopmental disorder-craniofacial dysmorphism-cardiac defect-hip dysplasia syndrome due to 9q21 microdeletion 10.4 MYCN RB1
17 watson syndrome 10.4 NF1 NF2
18 extracutaneous mastocytoma 10.4 MYCN RB1 RBL1
19 lateral medullary syndrome 10.4 NF1 NF2 NUMBL
20 jejunal somatostatinoma 10.4 ENO2 NF1 NF2
21 ampulla of vater neoplasm 10.4 CDKN2A CDKN2B TP53
22 cervical adenoid cystic carcinoma 10.4 NF1 TP53
23 clear cell adenofibroma 10.4 CDKN2A TP53
24 uterine disease 10.4 CDKN2A CDKN2B TP53
25 apocrine sweat gland neoplasm 10.4 CDK4 CDKN2A RB1
26 acute allergic sanguinous otitis media 10.4 BCL2 CCND1 CDKN1A
27 diphtheria 10.4 ENO2 NF1 NF2
28 epidural abscess 10.4 ENO2 NF1 NF2
29 prinzmetal's variant angina 10.4 CASP3 CDK2 MYC
30 his bundle tachycardia 10.4 BCL2 CCND1 TP53
31 oro-mandibular-limb hypogenesis syndrome 10.4 CCND1 CDKN2A TP53
32 brain stem medulloblastoma 10.4 CCND1 CDKN2A TP53
33 monckeberg arteriosclerosis 10.4 CDKN2A CDKN2B NF1 NF2
34 rommen mueller sybert syndrome 10.4 CDK4 TP53
35 childhood central nervous system primitive neuroectodermal neoplasm 10.4 ENO2 MYCN TP53
36 episodic ataxia 10.4 CCND1 CDK4 CDKN2A
37 house allergic alveolitis 10.4 CDK4 CDKN2A TP53
38 statin toxicity 10.4 BCL2 CCND1 TP53
39 duodenal ulcer 10.4 MYC MYCN TP53
40 lacrimal gland adenoid cystic carcinoma 10.4 CDKN2A TP53
41 perineural angioma 10.4 CDKN1A ENO2 TP53
42 pathologic nystagmus 10.4 CDKN2A NF1 NF2
43 multiple chemical sensitivity 10.4 ENO2 RBL1 TP53
44 urinary tract obstruction 10.4 CDKN1A ENO2 MYCN
45 skeletal tuberculosis 10.4 CCND1 CDKN2A
46 vascular myelopathy 10.4 CDKN2A NF1 NF2 TP53
47 fragile x-associated tremor/ataxia syndrome 10.4 CDKN2A ENO2 TP53
48 gallbladder pleomorphic giant cell adenocarcinoma 10.4 CDKN2A ENO2 TP53
49 gallbladder papillomatosis 10.4 BCL2 CDKN1A TP53
50 adult epithelioid sarcoma 10.4 CDKN2A ENO2 TP53

Graphical network of the top 20 diseases related to Nervous System Cancer:



Diseases related to Nervous System Cancer

Symptoms & Phenotypes for Nervous System Cancer

GenomeRNAi Phenotypes related to Nervous System Cancer according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 10.13 RB1 TP53 BCL2 CASP3 CDK2 CDKN1A
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 10.13 TP53 BCL2 CASP3 CDK2 CDKN1A CDKN2A
3 Upregulation of Wnt/beta-catenin pathway after WNT3A stimulation GR00016-A 9.02 CDK2 CDK4 ENO2 MYCN RBL1

MGI Mouse Phenotypes related to Nervous System Cancer:

44 (show all 27)
id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.55 BCL2 CASP3 CCND1 CDK2 CDK4 CDKN1A
2 growth/size/body region MP:0005378 10.52 BCL2 CASP3 CCND1 CDK2 CDK4 CDKN1A
3 behavior/neurological MP:0005386 10.51 NUMBL RB1 RBL1 TP53 BCL2 CASP3
4 homeostasis/metabolism MP:0005376 10.5 RBL1 TP53 BCHE BCL2 CASP3 CCND1
5 hematopoietic system MP:0005397 10.48 BCL2 CASP3 CCND1 CDK2 CDK4 CDKN1A
6 endocrine/exocrine gland MP:0005379 10.47 MYC NF1 NF2 RB1 RBL1 TP53
7 cardiovascular system MP:0005385 10.44 BCL2 CASP3 CCND1 CDK2 CDK4 CDKN1A
8 mortality/aging MP:0010768 10.44 BCHE BCL2 CASP3 CCND1 CDK2 CDK4
9 immune system MP:0005387 10.43 BCL2 CASP3 CCND1 CDK2 CDK4 CDKN1A
10 digestive/alimentary MP:0005381 10.42 MYC MYCN NF1 RB1 RBL1 TP53
11 integument MP:0010771 10.42 MYC NF1 NF2 RB1 RBL1 TP53
12 craniofacial MP:0005382 10.4 MYCN NF1 NF2 RB1 RBL1 TP53
13 embryo MP:0005380 10.38 NF2 NUMBL RB1 RBL1 TP53 CDK2
14 nervous system MP:0003631 10.36 MYCN NF1 NF2 NUMBL RB1 RBL1
15 neoplasm MP:0002006 10.35 RBL1 TP53 BCL2 CCND1 CDK2 CDK4
16 liver/biliary system MP:0005370 10.3 CDK2 CDK4 CDKN1A CDKN2A GNRH1 MYC
17 hearing/vestibular/ear MP:0005377 10.28 BCL2 CASP3 CDKN1A MYC NF1 NF2
18 muscle MP:0005369 10.27 RB1 RBL1 TP53 BCL2 CASP3 CDK2
19 reproductive system MP:0005389 10.19 BCHE BCL2 CASP3 CCND1 CDK2 CDK4
20 normal MP:0002873 10.1 CCND1 CDK4 GNRH1 MYC MYCN NF1
21 renal/urinary system MP:0005367 10.1 RBL1 TP53 BCL2 CASP3 CDK4 CDKN1A
22 no phenotypic analysis MP:0003012 10.09 CASP3 CDKN1A CDKN2A CDKN2B MYC MYCN
23 limbs/digits/tail MP:0005371 10.08 CDKN1A MYC MYCN NF1 RB1 RBL1
24 pigmentation MP:0001186 9.97 BCL2 CASP3 CDK4 CDKN2A MYC NF1
25 respiratory system MP:0005388 9.93 BCL2 CASP3 CCND1 CDKN1A CDKN2A ENO2
26 skeleton MP:0005390 9.73 CDKN2A GNRH1 MYC MYCN NF1 NF2
27 vision/eye MP:0005391 9.44 RB1 RBL1 TP53 BCL2 CASP3 CCND1

Drugs & Therapeutics for Nervous System Cancer

Drugs for Nervous System Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1393)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
2
Dacarbazine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 4342-03-4 5351166
3
Vindesine Approved Phase 4,Phase 3,Phase 2 59917-39-4, 53643-48-4 40839
4
Hydrocortisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-23-7 5754 657311
5
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 53-03-2 5865
6
Ranibizumab Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 347396-82-1 459903
7
Acetaminophen Approved Phase 4,Phase 2,Phase 3,Phase 1 103-90-2 1983
8
Bupivacaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 2180-92-9, 38396-39-3 2474
9
Epinephrine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51-43-4 5816
10
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 437-38-7 3345
11
Ketorolac Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 74103-06-3, 66635-83-4 3826
12
Morphine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 57-27-2 5288826
13
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 2078-54-8 4943
14
Menthol Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 2216-51-5 16666
15
Ketamine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 6740-88-1 3821
16
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 76631-46-4, 113775-47-6 68602 5311068 56032
17
Lidocaine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 137-58-6 3676
18
Oxaliplatin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 61825-94-3 5310940 9887054 6857599, 9887054 43805
19
Armodafinil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 112111-43-0
20
Modafinil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 68693-11-8 4236
21
Levobupivacaine Approved Phase 4,Phase 2,Phase 3 27262-47-1 92253
22
Midazolam Approved, Illicit Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 59467-70-8 4192
23
Acetylcholine Approved Phase 4,Phase 3,Phase 2,Phase 1 51-84-3 187
24
Remifentanil Approved Phase 4,Phase 3 132875-61-7 60815
25
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-78-2 2244
26
Pantoprazole Approved Phase 4 102625-70-7 4679
27
Ticlopidine Approved Phase 4 55142-85-3 5472
28
Celecoxib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 169590-42-5 2662
29 Parecoxib Approved Phase 4,Phase 3 198470-84-7
30
Tramadol Approved, Investigational Phase 4,Phase 1,Phase 2 27203-92-5 33741
31
Carboplatin Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 41575-94-4 10339178 498142 38904
32
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 159351-69-6 6442177
33
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 22916-47-8 4189
34
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 33069-62-4 36314
35
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 53123-88-9 5284616 6436030 46835353
36
Etanercept Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 185243-69-0
37
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1 51-61-6, 62-31-7 681
38
Methylphenidate Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 113-45-1 4158
39
Imiquimod Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 99011-02-6 57469
40
Temozolomide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 85622-93-1 5394
41
Etoposide Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 33419-42-0 36462
42
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 2068-78-2, 57-22-7 5978
43
Lamivudine Approved, Investigational Phase 4,Phase 3 134678-17-4 60825
44
Ropivacaine Approved Phase 4,Phase 3,Phase 2,Early Phase 1 84057-95-4 71273 175805
45
Mitoxantrone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 65271-80-9 4212
46
Ibuprofen Approved Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 15687-27-1 3672
47
Cytarabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 147-94-4 6253
48
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 1959-05-2, 59-05-2 126941
49
Sevoflurane Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 28523-86-6 5206
50
Hydromorphone Approved, Illicit Phase 4,Phase 3,Phase 2,Phase 1 466-99-9 5284570

Interventional clinical trials:

(show top 50) (show all 8842)
id Name Status NCT ID Phase
1 Correlation Between SV2A Expression in Tumour Tissue and Efficacy of Levetiracetam in Glioma Patients With Epilepsy Unknown status NCT00454935 Phase 4
2 Disease-Specific Questionnaire in Assessing Quality of Life in Patients With Gastrointestinal-Related Neuroendocrine Tumors Unknown status NCT00454376 Phase 4
3 Standard Palliative Care Versus Standard Palliative Care Plus Polychemotherapy in Metastasized Malignant Melanoma Unknown status NCT00226473 Phase 4
4 Effect of Perioperative Glucocorticoid Replacement on Prognosis of Surgical Patients With Sellar Lesions Unknown status NCT02190994 Phase 4
5 Intravitreal Ranibizumab for the Prevention of Radiation Maculopathy Following Plaque Radiotherapy Unknown status NCT00540930 Phase 4
6 Serratus Anterior Plane Block Versus Paravertebral Block for Postmastectomy Analgesia Unknown status NCT02103946 Phase 4
7 Comparison of the Vocal Cord Imaging Techniques After Thyroidectomy Unknown status NCT02410928 Phase 4
8 Characterization of Receptors in Non-functioning Pituitary Macroadenomas Unknown status NCT00852501 Phase 4
9 Effect of Ketalar to Prevent Postoperative Chronic Pain After Mastectomy Unknown status NCT00129597 Phase 4
10 A Comparison of Morphine and Morphine Plus Dexmedetomidine in Chronic Cancer Pain Unknown status NCT02289261 Phase 4
11 Paracetamol for Cancer Pain Unknown status NCT01313247 Phase 4
12 NK Activity Modulation Induced by Intravenous Lidocaine During Colorectal Laparoscopic Surgery Unknown status NCT01841294 Phase 4
13 Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer Unknown status NCT00274885 Phase 4
14 The Efficacy and Tolerability of Modafinil for Fatigue and Daytime Sleepiness in Cancer Patients: Preliminary Study Unknown status NCT02385656 Phase 4
15 Quadratus Lumborum Block for Percutaneous Nephrostomy Unknown status NCT02121951 Phase 4
16 Forehead Scars Following Mohs Micrographic Surgery and Reconstruction for Skin Cancer Unknown status NCT01459666 Phase 4
17 Safety Evaluation of Dexmedetomidine for EBUS-TBNA Unknown status NCT01381627 Phase 4
18 Does Early Re-administration of Aspirin/Clopidogrel Increase the Risk of Bleeding From Artificial Ulcer After EMR or ESD? Unknown status NCT01621451 Phase 4
19 Effect of COX-2 Selective Inhibitors on Postoperative Insulin Resistance After Gastrointestinal Laparoscopic Surgery Unknown status NCT01930318 Phase 4
20 The Risk of Bleeding After Removal of Large Colorectal Polyps in Patients Taking Aspirin Unknown status NCT01549418 Phase 4
21 Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer Completed NCT00953277 Phase 4
22 Pathophysiology of Post Amputation Pain Completed NCT01632709 Phase 4
23 Impact of Local Anesthesia Type on Cancer Detection Rate in Transrectal Ultrasound Guided Prostate Biopsy Completed NCT02025361 Phase 4
24 Phase IV Bioseal Study in Brain Tumor Surgery Completed NCT02034799 Phase 4
25 RAD001 With Paclitaxel and Carboplatin in First Line Treatment of Patients With Advanced Large Cell Lung Cancer With Neuroendocrine Differentiation Completed NCT01317615 Phase 4
26 Extension Study to the Open-label, Multi-center, Expanded Access Study of Everolimus in Patients With Advanced Neuroendocrine Tumors Completed NCT01595009 Phase 4
27 Somatuline Autogel Preference and Health Economy Study Completed NCT00681187 Phase 4
28 Efficacy of Prophylactic Itraconazole in High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation Completed NCT00336531 Phase 4
29 Scalp Nerve Block and Opioid Consumption in Brain Surgery Completed NCT02057367 Phase 4
30 Can We Miss Pigmented Lesions in Psoriasis Patients? Completed NCT01053819 Phase 4
31 NF1-Attention: Study of Children With Neurofibromatosis Type 1 Treated by Methylphenidate Completed NCT00169611 Phase 4
32 Post-Operative Drainage Following Lymph Node Dissection Completed NCT00324272 Phase 4
33 Randomized Clinical Trial of Posterior Retroperitoneoscopic Adrenalectomy Versus Lateral Laparoscopic Adrenalectomy Completed NCT01959711 Phase 4
34 Effect of Topical Imiquimod on Lentigo Maligna Completed NCT01161888 Phase 4
35 Standard Temodal (Temozolomide) Regimen Versus Standard Regimen Plus Early Postsurgery Temodal for Newly Diagnosed Glioblastoma Multiforme (Study P05572) Completed NCT00686725 Phase 4
36 Long Term Results of Combined Transpupillary Thermotherapy (TTT) Indocyanine Green (ICG) Based Photodynamic Therapy (PDT) in Choroidal Melanoma Completed NCT01253759 Phase 4
37 CEV With/Without Periocular Carboplatin Chemotherapy for Extraocular Retinoblastoma Completed NCT02319486 Phase 4
38 Early Intervention for Erectile Dysfunction After Laparoscopic Resection for Rectal Cancer Completed NCT01912586 Phase 4
39 The Use of Fentanyl in General Anesthesia for Craniotomy With or Without 0.5% Levobupivacaine Scalp Block Completed NCT02558569 Phase 4
40 The Efficacy of Penile Rehabilitation Using Udenafil After Total Mesorectal Excision of Rectal Cancer Completed NCT01421940 Phase 4
41 Prevention of Post-Mastectomy Breast Pain Using Ambulatory Continuous Paravertebral Blocks Completed NCT01231204 Phase 4
42 A Study of Tadalafil After Radical Prostatectomy Completed NCT01026818 Phase 4
43 A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy Completed NCT00106392 Phase 4
44 TAP Block in DIEP or Free MS-TRAM Donor Site: A RCT Completed NCT01398982 Phase 4
45 Long-Term Lamivudine Therapy for Chronic Hepatitis B Completed NCT00120354 Phase 4
46 Effects of Dexmedetomidine Used in Continuous Thoracic Paravertebral Blocks Completed NCT02619513 Phase 4
47 A Pilot Study of Mitoxantrone for the Treatment of Recurrent Neuromyelitis Optica (Devic’s Disease) Completed NCT00304291 Phase 4
48 Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen Completed NCT00346216 Phase 4
49 Long Term Study of Avonex Therapy Following a First Attack of Multiple Sclerosis Completed NCT00179478 Phase 4
50 Bioequivalence Study of Temozolomide in Patients With Primary Tumors of the Central Nervous System Completed NCT02343081 Phase 4

Search NIH Clinical Center for Nervous System Cancer

Cochrane evidence based reviews: neoplasms, nerve tissue

Genetic Tests for Nervous System Cancer

Genetic tests related to Nervous System Cancer:

id Genetic test Affiliating Genes
1 Neoplasm of the Nervous System 29

Anatomical Context for Nervous System Cancer

MalaCards organs/tissues related to Nervous System Cancer:

39
Brain

The Foundational Model of Anatomy Ontology organs/tissues related to Nervous System Cancer:

18
The Nervous System

Publications for Nervous System Cancer

Articles related to Nervous System Cancer:

(show all 23)
id Title Authors Year
1
Meta-Analysis of the Effects of Neuropsychological Interventions on Cognitive Function in Non-Central Nervous System Cancer Survivors. ( 27151596 )
2016
2
Five-year relative survival rate of brain and other nervous system cancer in the USA, Europe and Japan. ( 25717112 )
2015
3
Clinical characteristics, pathophysiology, and management of noncentral nervous system cancer-related cognitive impairment in adults. ( 25483452 )
2015
4
Stat Bite Number of New Brain and Other Nervous System Cancer Cases By Race/Ethnicity & Sex (2008-2012). ( 26538626 )
2015
5
Brain and central nervous system cancer incidence in navarre (Spain), 1973-2008 and projections for 2014. ( 25561983 )
2015
6
Identification of miRNAs as potential new biomarkers for nervous system cancer. ( 25139093 )
2014
7
Vocational identity, positive affect, and career thoughts in a group of young adult central nervous system cancer survivors. ( 25035908 )
2014
8
Detection of MGMT, RASSF1A, p15INK4B, and p14ARF promoter methylation in circulating tumor-derived DNA of central nervous system cancer patients. ( 23661397 )
2013
9
Medulloblastoma and Brucellosis - Molecular Evidence of Brucella sp in Association with Central Nervous System Cancer. ( 21475718 )
2011
10
Comparison of time trends in brain and central nervous system cancer mortality (1990-2006) between countries based on the WHO mortality database. ( 21273379 )
2011
11
Long-term health experience of jet engine manufacturing workers: IV. A comparison of central nervous system cancer ascertainment using mortality and incidence data. ( 20816315 )
2010
12
Pain in children with central nervous system cancer: a review of the literature. ( 20591796 )
2010
13
Induction of cytotoxicity, apoptosis and cell cycle arrest by 1-t-butyl carbamoyl, 7-methyl-indole-3-ethyl isothiocyanate (NB7M) in nervous system cancer cells. ( 19920894 )
2009
14
School-aged children after the end of successful treatment of non-central nervous system cancer: longitudinal assessment of health-related quality of life, anxiety and coping. ( 19594611 )
2009
15
Neuropsychological sequelae of non-central nervous system cancer and cancer therapy. ( 18415683 )
2008
16
Molecular predictors of human nervous system cancer responsiveness to enediyne chemotherapy. ( 18338171 )
2008
17
Comparison of time trends in brain central nervous system cancer incidence (1973-97) in East Asia, Europe and USA, from Cancer Incidence in Five Continents Vols IV-VIII. ( 18772173 )
2008
18
Cytotoxicity and oncostatic activity of the thiazolidinedione derivative CGP 52608 on central nervous system cancer cells. ( 15194216 )
2004
19
Nervous system cancer mortality in an industrialized area of Brazil 1980-1993. ( 10920400 )
2000
20
Exploitation of immune mechanisms in the treatment of central nervous system cancer. ( 10914414 )
2000
21
Risk of nervous system cancer among workers exposed to lead. ( 8673517 )
1996
22
Human malignant astrocytoma xenografts migrate in rat brain: a model for central nervous system cancer research. ( 2651679 )
1989
23
Brain and central nervous system cancer mortality in U. S. rubber workers. ( 6953785 )
1982

Variations for Nervous System Cancer

Expression for Nervous System Cancer

Search GEO for disease gene expression data for Nervous System Cancer.

Pathways for Nervous System Cancer

Pathways related to Nervous System Cancer according to GeneCards Suite gene sharing:

(show top 50) (show all 86)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
14 BCL2 CASP3 CCND1 CDK2 CDK4 CDKN1A
2
Show member pathways
13.83 BCL2 CCND1 CDK2 CDK4 CDKN1A CDKN2A
3
Show member pathways
13.56 CCND1 CDK2 CDK4 CDKN1A CDKN2A CDKN2B
4
Show member pathways
13.23 CDK2 CDK4 CDKN1A CDKN2A CDKN2B RB1
5
Show member pathways
13.17 BCL2 CCND1 CDK2 CDK4 CDKN1A CDKN2A
6
Show member pathways
13.08 BCL2 CASP3 CCND1 CDK2 CDK4 CDKN1A
7
Show member pathways
12.91 BCL2 CASP3 CDKN1A CDKN2A MYC TP53
8
Show member pathways
12.85 CASP3 CCND1 CDK2 CDK4 TP53
9
Show member pathways
12.85 CCND1 CDK2 CDK4 CDKN1A MYC RB1
10 12.77 BCL2 CCND1 CDK2 CDK4 CDKN1A MYC
11 12.74 BCL2 CASP3 CCND1 CDK2 CDK4 CDKN1A
12 12.7 BCL2 CASP3 CCND1 CDKN1A CDKN2A MYC
13
Show member pathways
12.68 BCL2 CCND1 CDKN1A MYC NUMBL
14 12.68 CCND1 CDK2 CDK4 CDKN1A CDKN2A RB1
15
Show member pathways
12.65 CCND1 CDK2 CDK4 CDKN1A CDKN2A CDKN2B
16
Show member pathways
12.64 CASP3 CCND1 MYC RB1 TP53
17 12.63 CCND1 CDK4 CDKN1A CDKN2A CDKN2B MYC
18 12.61 CCND1 CDK2 CDK4 MYC RB1 RBL1
19
Show member pathways
12.53 BCL2 CASP3 CCND1 CDKN1A MYC TP53
20
Show member pathways
12.49 CASP3 CCND1 CDK2 CDK4 CDKN1A CDKN2A
21 12.48 BCL2 CDK2 CDKN1A MYC RB1 TP53
22
Show member pathways
12.46 CCND1 CDK2 CDK4 CDKN1A CDKN2A CDKN2B
23
Show member pathways
12.44 CCND1 CDKN1A MYC TP53
24 12.43 CASP3 CCND1 CDKN1A MYC TP53
25
Show member pathways
12.43 BCL2 CASP3 CCND1 CDK2 CDK4 CDKN1A
26
Show member pathways
12.41 CDK2 CDKN1A RB1 TP53
27
Show member pathways
12.38 CCND1 CDK2 CDK4 CDKN1A CDKN2A CDKN2B
28
Show member pathways
12.37 CCND1 CDKN1A MYC TP53
29 12.33 CASP3 CCND1 CDKN1A MYC TP53
30
Show member pathways
12.33 CASP3 CCND1 CDK2 CDK4 CDKN1A MYC
31 12.32 CCND1 CDK2 CDK4 CDKN1A CDKN2A CDKN2B
32 12.31 BCL2 CASP3 MYC MYCN
33 12.31 CDKN1A MYC MYCN TP53
34
Show member pathways
12.3 CCND1 CDK4 CDKN1A CDKN2A MYC RB1
35
Show member pathways
12.28 BCL2 CCND1 CDKN1A MYC
36 12.28 BCL2 CCND1 CDK2 CDK4 CDKN1A CDKN2A
37 12.26 CCND1 CDKN1A CDKN2B MYC RBL1 TP53
38 12.21 CASP3 CCND1 CDK2 CDK4 MYC RB1
39 12.21 BCL2 CASP3 CCND1 CDK2 CDK4 MYC
40 12.2 BCL2 CCND1 CDKN1A TP53
41
Show member pathways
12.18 CCND1 CDK2 CDKN1A CDKN2B
42 12.18 BCL2 CCND1 CDKN1A CDKN2A MYC TP53
43 12.16 BCL2 CDKN1A RB1 TP53
44 12.16 BCL2 CCND1 CDKN1A MYC TP53
45 12.16 CASP3 CCND1 CDK2 CDK4 CDKN1A CDKN2A
46
Show member pathways
12.15 CCND1 CDK2 CDK4 NF1
47 12.12 BCL2 CDKN1A CDKN2A RB1 TP53
48
Show member pathways
12.04 CDK2 CDKN1A RBL1 TP53
49 12.02 BCL2 CASP3 CCND1 CDK4
50 12.01 CCND1 CDK2 CDK4 CDKN1A MYC RB1

GO Terms for Nervous System Cancer

Cellular components related to Nervous System Cancer according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 nucleoplasm GO:0005654 9.9 BCL2 CASP3 CCND1 CDK2 CDK4 CDKN1A
2 transcription factor complex GO:0005667 9.67 CDK2 CDK4 RB1 RBL1
3 nucleolus GO:0005730 9.56 CDK4 CDKN1A CDKN2A MYC MYCN NF1
4 cyclin-dependent protein kinase holoenzyme complex GO:0000307 8.92 CCND1 CDK2 CDK4 CDKN1A
5 cytosol GO:0005829 10.13 BCL2 CASP3 CCND1 CDK2 CDK4 CDKN1A
6 nucleus GO:0005634 10.13 BCL2 CASP3 CCND1 CDK2 CDK4 CDKN1A

Biological processes related to Nervous System Cancer according to GeneCards Suite gene sharing:

(show all 49)
id Name GO ID Score Top Affiliating Genes
1 regulation of gene expression GO:0010468 9.97 BCL2 CDK4 GNRH1 MYC NF1
2 cell cycle GO:0007049 9.97 CCND1 CDK2 CDK4 CDKN1A CDKN2A CDKN2B
3 negative regulation of gene expression GO:0010629 9.96 CDKN1A MYC MYCN RB1 RBL1
4 response to organic cyclic compound GO:0014070 9.94 CASP3 CCND1 CDKN1A GNRH1
5 negative regulation of cell growth GO:0030308 9.92 BCL2 CDKN1A CDKN2A TP53
6 negative regulation of protein kinase activity GO:0006469 9.89 CDKN2A NF1 NF2 RB1
7 response to organic substance GO:0010033 9.89 CASP3 CCND1 CDK2 CDK4 CDKN1A
8 regulation of protein stability GO:0031647 9.87 BCL2 CDKN2A NF2
9 DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest GO:0006977 9.87 CDK2 CDKN1A TP53
10 positive regulation of fibroblast proliferation GO:0048146 9.86 CDK4 CDKN1A MYC
11 animal organ regeneration GO:0031100 9.85 CCND1 CDK4 CDKN1A
12 positive regulation of neuron apoptotic process GO:0043525 9.85 CASP3 NF1 TP53
13 cell cycle arrest GO:0007050 9.85 CDKN1A CDKN2A CDKN2B MYC RB1 TP53
14 regulation of mitotic cell cycle GO:0007346 9.83 CDKN1A MYC RB1
15 positive regulation of cell cycle GO:0045787 9.83 CCND1 CDK4 MYC
16 response to glucocorticoid GO:0051384 9.83 BCHE